Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415749 · ClinicalTrials.gov registry record · Phase 1
NasoShield in Healthy Adults to Study Safety and Immunogenicity
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT04415749 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 43 participants.
The verdict
NCT04415749, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.
Interventions
- OTHER Placebo
- BIOLOGICAL NasoShield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2021-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415749
The ClinicalTrials.gov registry entry for NCT04415749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04415749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04415749 about?
NCT04415749 is a clinical study titled "NasoShield in Healthy Adults to Study Safety and Immunogenicity". The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to determine if antibodies that protect against anthrax are formed after treatment with NasoShield, and to determine whether the formation of these antibodies are affected by different positions of administration.
What is the current status of trial NCT04415749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2020-06-15. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT04415749?
The interventions under investigation include: Placebo (OTHER), NasoShield (BIOLOGICAL).
Who is sponsoring clinical trial NCT04415749?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.